Literature DB >> 18020041

Baclofen as prophylaxis and treatment for alcohol withdrawal: a retrospective chart review.

William Stallings1, Stuart Schrader.   

Abstract

CONTEXT: Current standard of care for alcohol withdrawal is accomplished using benzodiazepines. There are no recommendations for prophylaxis of alcohol withdrawal in high risk populations. Baclofen has been studied for the treatment of alcohol withdrawal, but current research is limited.
OBJECTIVE: To determine if baclofen is an effective measure for prophylaxis and treatment of alcohol withdrawal in high risk populations upon admission to hospital wards. Design, Setting, Patients - Retrospective chart review of 42 inpatients at St. Anthony Hospital from November 2004 to April 2005. Patients were included if they were determined to be at risk for alcohol withdrawal. Patients were then divided into categories of prophylactic success versus failure and treatement success versus failure based on DSM-IV criteria for alcohol withdrawal.
RESULTS: 17 patients were included in the study. 12 were categorized as prophylactic success and 2 were categorized as prophylactic failure. There was one treatment success and two treatment failures. The result was an 86% prophylactic success rate.
CONCLUSIONS: Baclofen has potential in the prophylaxis of alcohol withdrawal. It is difficult to determine the clinical significance for the numbers found in this study. There are no prior studies for alcohol prophylaxis to compare what would be an acceptable success rate. Further studies that are double-blinded placebo controlled are needed to support or refute the usefulness of baclofen for alcohol withdrawal.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18020041

Source DB:  PubMed          Journal:  J Okla State Med Assoc        ISSN: 0030-1876


  11 in total

Review 1.  Identification and management of alcohol withdrawal syndrome.

Authors:  Antonio Mirijello; Cristina D'Angelo; Anna Ferrulli; Gabriele Vassallo; Mariangela Antonelli; Fabio Caputo; Lorenzo Leggio; Antonio Gasbarrini; Giovanni Addolorato
Journal:  Drugs       Date:  2015-03       Impact factor: 9.546

Review 2.  Baclofen for alcohol withdrawal.

Authors:  Jia Liu; Lu-Ning Wang
Journal:  Cochrane Database Syst Rev       Date:  2017-08-20

Review 3.  Novel therapeutic strategies for alcohol and drug addiction: focus on GABA, ion channels and transcranial magnetic stimulation.

Authors:  Giovanni Addolorato; Lorenzo Leggio; F Woodward Hopf; Marco Diana; Antonello Bonci
Journal:  Neuropsychopharmacology       Date:  2011-10-26       Impact factor: 7.853

Review 4.  Alcoholic liver disease: treatment.

Authors:  Ki Tae Suk; Moon Young Kim; Soon Koo Baik
Journal:  World J Gastroenterol       Date:  2014-09-28       Impact factor: 5.742

5.  Baclofen for alcohol withdrawal.

Authors:  Jia Liu; Lu-Ning Wang
Journal:  Cochrane Database Syst Rev       Date:  2019-11-06

6.  The GABA B agonist baclofen reduces cigarette consumption in a preliminary double-blind placebo-controlled smoking reduction study.

Authors:  Teresa R Franklin; Derek Harper; Kyle Kampman; Susan Kildea-McCrea; Will Jens; Kevin G Lynch; Charles P O'Brien; Anna Rose Childress
Journal:  Drug Alcohol Depend       Date:  2009-04-23       Impact factor: 4.492

7.  Baclofen in the management of cannabis dependence syndrome.

Authors:  Bruce Imbert; Nathalie Labrune; Christophe Lancon; Nicolas Simon
Journal:  Ther Adv Psychopharmacol       Date:  2014-02

8.  Clinical experience of baclofen in alcohol dependence: A chart review.

Authors:  Abhijit R Rozatkar; Abhishek Kapoor; Ajeet Sidana; Bir Singh Chavan
Journal:  Ind Psychiatry J       Date:  2016 Jan-Jun

Review 9.  GABAB receptor ligands for the treatment of alcohol use disorder: preclinical and clinical evidence.

Authors:  Roberta Agabio; Giancarlo Colombo
Journal:  Front Neurosci       Date:  2014-06-06       Impact factor: 4.677

Review 10.  The Use of Baclofen as a Treatment for Alcohol Use Disorder: A Clinical Practice Perspective.

Authors:  Renaud de Beaurepaire; Julia M A Sinclair; Mathis Heydtmann; Giovanni Addolorato; Henri-Jean Aubin; Esther M Beraha; Fabio Caputo; Jonathan D Chick; Patrick de La Selle; Nicolas Franchitto; James C Garbutt; Paul S Haber; Philippe Jaury; Anne R Lingford-Hughes; Kirsten C Morley; Christian A Müller; Lynn Owens; Adam Pastor; Louise M Paterson; Fanny Pélissier; Benjamin Rolland; Amanda Stafford; Andrew Thompson; Wim van den Brink; Lorenzo Leggio; Roberta Agabio
Journal:  Front Psychiatry       Date:  2019-01-04       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.